Research & Publications

Research abstract: Real-World 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members Without Diabetes

Prime study finds the cost of GLP-1s continues to be a significant driver of total cost of care, which remained $4,490 higher in Year 3 compared to a matched control group

Research abstract

About Prime Therapeutics

Prime Therapeutics logo

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn

Latest News